Aggrecan Antibody, N-terminal neoepitope ARGSVIL
Please register to view price.
Please inquire, bulk orders available.
Mouse Monoclonal Antibody to Aggrecan N-terminal neoepitope ARGSVIL.
Overview
Proteoglycans are categoried depending upon the nature of their glycosaminoglycan chains (chondroitin sulfate, dermatan sulfate, heparan sulphate and keratan sullfate) as well as characterized by size.
Aggrecan is a large aggregating proteoglycan of articular cartilage. It is found also in aorta tissue, discs, tendons and in the perineuronal net. It is responsible for hydrating cartilage, giving it compressibility and resiliance during joint loading, thereby playing a major role in the normal function of cartilage. Depletion of glycosaminoglycan bearing aggrecan fragments is one of the earliest events in cartilage destruction.
A) Aggrecan monomer showing proteolytic cleavage sites
B) Aggregate showing aggrecan monomers bound to hyaluronic acid
Data/Specifications
Specificity: The antibody reacts with the N-terminal sequence ARGSVIL of aggrecan fragments produced by proteolysis at the aggrecanase site within the interglobular domain of aggrecan (aggrecan-IGD). It does not react to a significant extent with the sequence ARGSVIL contained within uncleaved polypeptide chains. ARGSVIL-peptides produced from recombinant aggrecan-IGD in the presence of aggrecanases bind strongly to the antibody both in Western Blots (see Fig 1) and in ELISA. ARSGVIL fragments derived from native aggrecan require prior deglycosylation for antibody binding.
Purity: Protein A
Form: Purified antibody in 100 μL phosphate buffer saline (20 mM Na-Phosphate, pH 7.5, 150 mM NaCl) containing 0.01% thimerosal.
Storage: -20° C
Literature/Support
Aggrecan Antibody, N-terminal neoepitope ARGSVIL Insert (PDF, 288 KB)
How To Use
Application
Western-Blotting with ECL-Detection.
Suggested antibody dilution 1:2000.